Recombinant follicle-stimulating hormone and recombinant luteinizing hormone versus recombinant follicle-stimulating hormone alone during GnRH antagonist ovarian stimulation in patients aged ≥35 years: A randomized controlled trial

Human Reproduction

Volumn 30, Issue 5, 2015, Pages 1188-1195

  Vuong, T N L ^a,b   Phung, H T ^b   Ho, M T ^b,c  

^a UNIVERSITY OF MEDICINE AND PHARMACY AT HO CHI MINH CITY   (Viet Nam)

^b IVFAS   (Viet Nam)

^c VIETNAM NATIONAL UNIVERSITY   (Viet Nam)

Author keywords

in vitro fertilization; luteinizing hormone supplementation; ovarian stimulation; recombinant follicle stimulating hormone; recombinant luteinizing hormone

Indexed keywords

CETRORELIX; RECOMBINANT FOLLITROPIN; RECOMBINANT FOLLITROPIN PLUS RECOMBINANT LUTEINIZING HORMONE; FOLLITROPIN; GONADORELIN; HORMONE ANTAGONIST; LUTEINIZING HORMONE; RECOMBINANT PROTEIN;

ADULT; ARTICLE; BIRTH RATE; CONTROLLED STUDY; FEMALE; FERTILIZATION IN VITRO; HUMAN; IMPLANTATION; MAJOR CLINICAL STUDY; OOCYTE RETRIEVAL; OUTCOME ASSESSMENT; OVARY HYPERSTIMULATION; PREGNANCY RATE; RANDOMIZED CONTROLLED TRIAL; SPONTANEOUS ABORTION; ANTAGONISTS AND INHIBITORS; OVULATION INDUCTION; PREGNANCY; PREGNANCY OUTCOME; PROCEDURES; SAMPLE SIZE; TREATMENT OUTCOME;

ADULT; BIRTH RATE; FEMALE; FERTILIZATION IN VITRO; FOLLICLE STIMULATING HORMONE; GONADOTROPIN-RELEASING HORMONE; HORMONE ANTAGONISTS; HUMANS; LUTEINIZING HORMONE; OVULATION INDUCTION; PREGNANCY; PREGNANCY OUTCOME; RECOMBINANT PROTEINS; SAMPLE SIZE; TREATMENT OUTCOME;

EID: 84929744949     PISSN: 02681161     EISSN: 14602350     Source Type: Journal    
DOI: 10.1093/humrep/dev038     Document Type: Article

References (23)

1. Bosch E, Escudero E, Crespo J, SimonC, Remohi J, Pellicer A. Serumluteinizing hormone in patients undergoing ovarian stimulation with gonadotropinreleasing hormone antagonists and recombinant follicle-stimulating hormone and its relationship with cycle outcome. Fertil Steril 2005; 84:1529-1532.
2. Bosch E, Labarta E, Crespo J, Simon C, Remohi J, Pellicer A. Impact of luteinizing hormone administration on gonadotropin-releasing hormone antagonist cycles: an age-Adjusted analysis. Fertil Steril 2011;95:1031-1036.
3. DeCherney AH, Berkowitz GS. Female fecundity and age.NEngl J Med 1982; 306:424-426.
4. Fabregues F, Creus M, Penarrubia J, Manau D, Vanrell JA, Balasch J. Effects of recombinant human luteinizing hormone supplementation on ovarian stimulation and the implantation rate in down-regulated women of advanced reproductive age. Fertil Steril 2006;85:925-931.
5. Ferraretti AP, Gianaroli L, Magli MC, D'angelo A, Farfali V, Montanaro N. Exogenous luteinizing hormone in controlled ovarian hyperstimulation for assisted reproductive techniques. Fertil Steril 2004;82:1251-1526.
6. Ferraretti AP, La Marca A, Fauser BCJM, Tarlatzis B, Nargund G, Gianaroli L, ESHRE working group on Poor Ovarian Response Definition. ESHRE consensus on the definition of poor response to ovarian stimulation for in vitro fertilization: the Bologna criteria. Hum Reprod 2011;26: 1616-1624.
7. Hill MJ, Levens ED, Levy G, Ryan ME, Csokmay JM, DeCherney AH, Whitcomb BW. The use of recombinant luteinizing hormone in patients undergoing assisted reproductive techniques with advanced reproductive age: a systematic reviewand meta-Analysis. Fertil Steril 2012;97:1108-1114.
8. Hillier SG. Gonadotropic control of ovarian follicular growth and development. Mol Cell Endocrinol 2001;179:39-46.
9. HumaidanP, BungumM, BungumL, YdlingAndersenC. Effectsof recombinant LH supplementation in women undergoing assisted reproduction with GnRH agonist down-regulation and stimulation with recombinant FSH; an opening study. Reprod Biomed Online 2004;8:635-643.
10. Kolibianakis EM, Kalogeropoulou L, Griesinger G, Papanikolaou EG, Papadimas J, Bontis J, Tarlatzis BC. Among patients treated with FSH and GnRH analogues for in vitro fertilization, is the addition of recombinant LH associated with the probability of live birth?. A systematic review and meta-Analysis. Hum Reprod Update 2007;13:445-452.
11. Konig TE, van der Houwen LEE, Overbeek A, Hendriks ML, Beutler-Beemsterboer SN, Kuchenbecker WKH, Renckens CNM, Bernardus RE, Schats R, Homburg R et al. Recombinant LH supplementation to a standard GnRH antagonist protocol in women of 35 years or older undergoing IVF/ICSI: a randomized controlled multicentre study. Hum Reprod 2013;28:2804-2812.
12. Lehert P, Kolibianakis EM, Venetis CA, Schertz J, Saunders H, Arriagada P, Copt S, Tarlatzis B. Recombinant human follicle-stimulating hormone (r-hFSH) plus recombinant luteinizing hormone versus r-hFSH alone for ovarian stimulation during assisted reproductive technology: systematic review and meta-Analysis. Reprod Biol Endocrinol 2014;12:17.
13. Marrs R, Meldrum D, Muasher S, Schoolcraft W, Werlin L, Kelly E. Randomized trial to compare the effect of recombinant human FSH (follitropin alfa) with or without recombinant human LH in women undergoing assisted reproduction treatment. Reprod Biomed Online 2004;8:175-182.
14. Mathur R, Evbuomwan I, Jenkins J. Prevention and management of ovarian hyperstimulation syndrome. Curr Obstet Gynaecol 2005;15:132-138.
15. Matorras R, Prieto B, Exposito A, Mendoza R, Crisol L, Herranz P, Burgues S. Mid-follicular LH supplementation in women aged 35-39 years undergoing ICSI cycles: a randomized controlled study. Reprod Biomed Online 2009;19:879-887.
16. Mochtar MH, Van der Veen F, Ziech M, van Wely M. Recombinant luteinizing hormone (rLH) for controlled ovarian hyperstimulation in assisted reproductive cycles. Cochrane Database Syst Rev 2007; 2:CD005070.
17. Purcell K, Schembri M, Frazier LM, Rall MJ, Shen S, CroughanM, GraingerDA, Fujimoto VY. Asian ethnicity is associated with reduced pregnancy outcomes after assisted reproductive technology. Fertil Steril 2007; 87:297-302.
18. Ramachandran A, Jamdade K, Kumar P, Adiga SK, Bhat RG, Ferrao SR. Is there a need for luteinizing hormone (LH) estimation in patients undergoing ovarian stimulation with gonadotropin-releasing hormone (GnRH) antagonists and recombinant follicle-stimulating hormone (rFSH)?. J Clin Diagn Res 2014;8:90-92.
19. Templeton A, Morris JK, ParslowW. Factors that affect outcome of in-vitro fertilisation treatment. Lancet 1996;348:1402-1406.
20. Vuong TNL, Ho MT, Pham VT, Nguyen TNP. The addition of recombinant LH in poor-responder IVF patients [abstract]. Presented at 18th World Congress on Fertility and Sterility, May 23-28, 2004; Montreal, Quebec, Canada (Abstract 307.6).
21. Vuong TNL, Nguyen KL, Ho MT, Wong PC, Howles CM. Anti-Mullerian hormone versus antral follicle stimulating count for defining the starting dose of FSH. Reprod Biomed Online 2013;27:390-399.
22. Wiser A, Hourvitz A, Yinon Y, Levron J, Dor J, Elizur SE. Recombinant human luteinizing hormone supplementationmay improve embryo quality in in vitro fertilization/intracytoplasmic sperm injection cycles with gonadotropinreleasinghormoneantagonistprotocol. Open JObstetGynecol 2011;1:31-35.
23. Wong PC, Qiao J, HoC, Ramaraju GA, Wiweko B, TakeharaY, Nadkarni PV, Cheng LC, Chen HF, Suwajanakorn S et al. Current opinion on use of luteinizing hormone supplementation in assisted reproduction therapy: an Asian perspective. Reprod Biomed Online 2011;23:81-90.